The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma.

ABSTRACT: The management of metastatic renal cell carcinoma (mRCC) continues to be a therapeutic challenge; however, the options for systemic therapy in this setting have exploded over the past 20 years. From the advent of toxic cytokine therapy to the subsequent discovery of targeted therapy (TT) and immune checkpoint inhibitors, the landscape of viable treatment options continues to progress. With the arrival of cytokine therapy, two randomized trials demonstrated a survival benefit for upfront cytoreductive nephrectomy (CN) plus interferon therapy and this approach became the standard for surgical candidates. However, it was difficult to establish the role and the timing of CN with the subsequent advent of TT, just a few years later. More recently, two randomized phase III studies completed in th

SUBMITTER: Umbreit EC 

PROVIDER: S-EPMC8033221 | biostudies-literature | 2021 Jan-Mar

REPOSITORIES: biostudies-literature